Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2018-11-13 Director's Dealing
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Otrzymanie zawiadomienia od osoby pełniącej obowiązki zarządcze - Content (PL)
Director's Dealing Classification · 1% confidence The document text is very short (456 characters) and explicitly states that a notification ('zawiadomienie') regarding a transaction by a person discharging managerial responsibilities (PDMR) under MAR Regulation Article 19 has been received, and the full content of this notification is attached ('Pełną treści zawiadomienia załączono do niniejszego raportu.'). This structure—a brief announcement stating an official document is attached—strongly suggests a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), based on the 'MENU VS MEAL' rule. Since the content describes a transaction by management (insider dealing), the most specific category that covers the *announcement* of such regulatory filings, especially when the actual detailed report is attached separately, is often RNS, but DIRS (Director's Dealing) covers the subject matter. However, because the text itself is merely announcing the *receipt* and *attachment* of the MAR 19 notification, and not the detailed transaction data itself, RPA or RNS is appropriate. Given the specific nature of the underlying event (insider transaction), and the fact that MAR 19 notifications are standard regulatory disclosures, RNS is a strong candidate if RPA is not the best fit. Since the document is announcing the publication/receipt of a regulatory notice, and it is not the detailed Director's Dealing report itself, RNS (General Regulatory Filings) is the most appropriate fallback/general regulatory category for this announcement structure, although RPA is also plausible. Given the context of MAR 19, which is a specific regulatory disclosure, RNS is chosen as the general regulatory announcement category.
2018-11-13 Polish
Zakończenie trzeciego etapu prac badawczo-rozwojowych nad systemem PCR|ONE - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from the Management Board (Zarząd) of Scope Fluidics regarding the completion of the third stage of R&D work on the PCRIONE system, specifically the development of the 'Clostridium difficile' panel by its subsidiary. This announcement details technical achievements (primer validation, sample lysis, chip development) and strategic importance. It is not a standard regulatory filing like 10-K, an earnings release (ER), or a dividend notice. It describes a significant operational/development milestone, which aligns best with a general corporate update or announcement that doesn't fit the highly specific categories like M&A (TAR) or Financing (CAP). Given the options, this type of operational/R&D progress update, especially when announced by management, is often categorized under general corporate reporting. Since it is not a presentation (IP), a formal report (AR, IR), or a management discussion (MDA), and it details internal progress, it fits best as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard announcements, or potentially a Management Report (MDA) if it were more focused on business trends, but RNS is safer for specific operational updates not covered elsewhere. However, since it is a direct announcement of a development milestone by the management board, and it is not a standard financial report, it falls under general corporate disclosure. I will classify it as RNS (Regulatory Filings) as the most appropriate fallback for a significant, non-financial, non-governance operational update.
2018-10-24 Polish
Zawarcie umowy przez spółkę zależną Emitenta - Content (PL)
Regulatory Filings Classification · 1% confidence The document text describes a strategic agreement signed by a subsidiary (Curiosity Diagnostics) with a partner (microfluidic ChipShop GmbH) to optimize the design and production of a PCR panel for the PCR|ONE system. This involves technical development, cost optimization, and planning for industrial production, which is described as a crucial step towards CE-IVD certification. This type of announcement details a significant business development, partnership, or strategic move related to product development and manufacturing readiness, rather than routine financial reporting (like 10-K, ER, IR) or governance events (like AGM, DIRS). It best fits the category for major corporate activities or strategic updates that are not explicitly covered by other codes. Since it details a significant business development/partnership aimed at product commercialization, it is classified as a general Regulatory Filing (RNS) as it doesn't fit the specific codes like M&A (TAR) or Financing (CAP). However, given the context of strategic development and partnership, it is a significant corporate event announcement. Since there is no specific 'Strategic Partnership' or 'Business Development' code, RNS (Regulatory Filings/Miscellaneous Announcement) is the most appropriate fallback.
2018-10-11 Polish
ESPI_2018_13_20180905_zalacznik.pdf
Director's Dealing Classification · 1% confidence The document is titled "Powiadomienie o transakeji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction/transactions referred to in Article 19(1) of the MAR Regulation). It details a transaction (Nabycie - Acquisition) of shares by a person discharging managerial responsibilities (Krzysztof Wiśniewski) in Scope Fluidics S.A. This type of filing, reporting insider transactions by management, directly corresponds to the definition of Director's Dealing (DIRS). The document is a specific regulatory disclosure concerning insider trading, not a general annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2018-09-05 Polish
Otrzymanie zawiadomienia od osoby pełniącej obowiązki zarządcze - Content (PL)
Director's Dealing Classification · 1% confidence The document text is very short (442 characters) and explicitly states that a notification ('zawiadomienie') regarding a transaction by a person discharging managerial responsibilities (PDMR) under MAR Regulation Article 19 has been received, and the full content of this notification is attached ('Pełną treść zawiadomienia załączono do niniejszego raportu.'). This structure—a brief announcement stating that the detailed report/notification is attached—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), based on the 'MENU VS MEAL' rule. Since the content specifically relates to insider transactions (Director's Dealing under MAR), the most precise category is Director's Dealing (DIRS). However, DIRS typically refers to the actual report of the transaction itself. Given the text is merely an announcement that the MAR notification (which is essentially a Director's Dealing report) has been filed and is attached, RPA or RNS is plausible. Since DIRS is a specific category for director transactions, and this document is announcing the filing of such a transaction report, I will check the definitions again. DIRS is defined as 'Report of personal share transactions by company directors and executives (insider trades).' The document is announcing the receipt of the MAR notification, which is the regulatory filing for insider trades. If the attached document contains the details, this announcement is best classified as a Regulatory Filing (RNS) or RPA. Given the context of MAR Article 19 filings, which are mandatory regulatory disclosures, RNS (General regulatory announcements) is a strong fit, as is RPA (Report Publication Announcement). Since the document is announcing the publication/receipt of a specific regulatory document, RPA is slightly more fitting than the general RNS fallback, but DIRS is the subject matter. Given the 'MENU VS MEAL' rule, this is an announcement, not the full report. I will classify it as RPA because it announces the publication/attachment of a report, which is the most accurate description of the document's function here.
2018-09-05 Polish
Zawarcie umowy z doradcą transakcyjnym w zakresie komercjalizacji projektu PCR|ONE - Content (PL)
M&A Activity Classification · 1% confidence The document text describes SCOPE FLUIDICS S.A. entering into an agreement with Clairfield Partners LLC to advise on the process of attracting a strategic investor interested in acquiring shares of a subsidiary (Curiosity Diagnostics Sp. z o.o.). This involves identifying potential buyers, due diligence support, and negotiation strategy for the sale of the subsidiary's shares. This activity directly relates to a potential merger, acquisition, or divestiture event. Reviewing the definitions: - 10-K/IR/ER/AR: Not a periodic financial report. - ER/MRQ: Not an earnings release or major shareholding notification. - CAP: While it involves financing/capital structure indirectly (sale of a subsidiary), the core action is the M&A advisory process. - TAR (M&A Activity): This category is defined as 'Announcements and documents related to merger proposals or takeover bids.' The engagement of an advisor specifically for the sale/acquisition of a significant asset (subsidiary shares) falls squarely under M&A activity. Therefore, the document is classified as M&A Activity (TAR).
2018-07-30 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.